Upcoming annual medical conferences where important clinical data realeases expected
NACF (national Cf meeting) Oct. 19
ACR (national rheumatology meeting) Oct 25
AASLD (national hepatology meeting) Nov 1 through Nov 5
Over the two weeks from Oct 19 through Nov 5 expect new data on the CF RA and hep C drugs in development from Vertex (if not released earlier), and well as announcements of partnership/licensing deals for ongoing development of VX 509 and VX 787. These represent a flurry of data that will likely enhance analyst valuation of VRTX projected growth over the next few years, and likely push the stock higher in price.
I have to say I'm getting concerned with the lack of progress/reports on any partnerships for RA and flu.....these lose shelf life over time as other researchers catch up. They're asking too much or nobody wants them which speaks to how effective they might (not) be. Might be just another, slightly better, version of what is on the market already.